Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) Director Bruce Polsky sold 8,720 shares of the business’s stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $4.03, for a total transaction of $35,141.60. Following the transaction, the director directly owned 158,580 shares of the company’s stock, valued at approximately $639,077.40. This represents a 5.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Bruce Polsky also recently made the following trade(s):
- On Wednesday, November 18th, Bruce Polsky sold 18,252 shares of Atea Pharmaceuticals stock. The stock was sold at an average price of $3.95, for a total transaction of $72,095.40.
- On Monday, November 16th, Bruce Polsky sold 14,254 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.27, for a total value of $60,864.58.
Atea Pharmaceuticals Stock Performance
Shares of AVIR stock opened at $3.99 on Thursday. The company has a market capitalization of $320.41 million, a P/E ratio of -2.05 and a beta of 0.76. Atea Pharmaceuticals, Inc. has a fifty-two week low of $2.92 and a fifty-two week high of $6.45. The stock has a 50 day moving average price of $4.70 and a two-hundred day moving average price of $4.94.
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.11. As a group, equities analysts predict that Atea Pharmaceuticals, Inc. will post -1.60 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Empowered Funds LLC bought a new position in shares of Atea Pharmaceuticals in the third quarter worth approximately $475,000. Engineers Gate Manager LP bought a new stake in shares of Atea Pharmaceuticals during the second quarter valued at approximately $78,000. Spark Investment Management LLC bought a new stake in shares of Atea Pharmaceuticals during the second quarter valued at approximately $75,000. Headlands Technologies LLC purchased a new position in Atea Pharmaceuticals in the 2nd quarter worth approximately $77,000. Finally, Wellington Management Group LLP raised its holdings in Atea Pharmaceuticals by 262.7% in the 2nd quarter. Wellington Management Group LLP now owns 206,785 shares of the company’s stock worth $962,000 after acquiring an additional 149,776 shares during the last quarter. 86.67% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
AVIR has been the topic of a number of analyst reports. Wall Street Zen raised Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research report on Thursday, October 15th. Finally, Morgan Stanley lifted their price objective on Atea Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.00.
Get Our Latest Analysis on Atea Pharmaceuticals
Atea Pharmaceuticals Company Profile
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.
Featured Articles
- Five stocks we like better than Atea Pharmaceuticals
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
